Shanghai InnoPha

InnoPha is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the discovery and development of novel small molecule drugs for challenging therapeutic targets. The company focuses on the RAS/MAPK signaling pathway, utilizing a proprietary platform that integrates structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) to target complex protein-protein interactions (PPIs). Its lead candidate, IPH-101, is a potent SHP2 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. InnoPha's pipeline also includes promising programs targeting SOS1 and KRAS, aimed at addressing unmet needs in oncology and overcoming drug resistance. The company is supported by a strong syndicate of investors, including Lilly Asia Ventures and Qiming Venture Partners, and is led by a team with extensive experience in global pharmaceutical R&D.